Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.15M | $23.6M | $77.4M | $130M | $190M |
| Revenue growth | — | — | — | — | — | — | 649.5% | 227.6% | 68.1% | 45.8% |
| Operating income | -$25.9M | -$32.4M | -$78.4M | -$146M | -$137M | -$170M | -$179M | -$184M | -$266M | -$192M |
| Operating margin | — | — | — | — | — | -5391.9% | -757.9% | -238.1% | -204.0% | -101.2% |
| Net income | -$25.9M | -$33.7M | -$74.1M | -$141M | -$134M | -$69.6M | -$181M | -$185M | -$261M | -$197M |
| Net margin | — | — | — | — | — | -2207.1% | -766.2% | -238.5% | -200.3% | -103.6% |
| EPS (diluted) | -$2.85 | -$2.83 | -$2.39 | -$3.86 | -$3.04 | -$1.40 | -$3.47 | -$3.20 | -$4.34 | -$3.11 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.2M | -$29.5M | -$62.1M | -$123M | -$122M | -$146M | -$173M | -$136M | -$114M | -$116M |
| Capital expenditures | $1.06M | $133K | $722K | $3.38M | $214K | $434K | $281K | $47.0K | $0.00 | $953K |
| Free cash flow | -$24.3M | -$29.6M | -$62.8M | -$126M | -$122M | -$146M | -$174M | -$136M | -$114M | -$117M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.54M | $34.2M | $49.5M | $62.3M | $101M | $59.2M | $128M | $60.1M | $89.1M | $54.3M |
| Total assets | $12.3M | $152M | $260M | $309M | $187M | $330M | $382M | $333M | $392M | $480M |
| Total liabilities | $5.04M | $6.95M | $14.0M | $27.5M | $20.5M | $45.4M | $118M | $163M | $228M | $210M |
| Long-term debt | — | — | — | — | — | — | — | $106M | $108M | $101M |
| Shareholders' equity | -$32.7M | $145M | $246M | $281M | $167M | $284M | $264M | $170M | $21.7M | $139M |
| Retained earnings | -$76.5M | -$110M | -$185M | -$325M | -$459M | -$529M | -$710M | -$895M | -$1.16B | -$1.35B |
| Shares (wtd avg diluted) | 10.2M | 27.3M | 34.4M | 36.4M | 44.1M | 49.6M | 52.1M | 57.7M | 61.0M | 65.0M |
Every figure is extracted from RHYTHM PHARMACEUTICALS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.